Amgen says Kyprolis doubles progression-free survival vs Velcade

March 1 (Reuters) - Amgen Inc's Kyprolis helped patients with relapsed multiple myeloma live twice as long before their blood cancer worsened compared to a regimen containing rival drug Velcade, according to an interim analysis announced by the company on Sunday.